Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Study Approval Paves the Way for Trial Participants to Begin Taking Apabetalone
CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX), today announces the approval of its COVID-19 clinical trial…
